文献速递眼底病与葡萄膜炎

视网膜临床试验失败的经验教训

Unsuccessful Clinical Trials in Retina: Lessons Learned.
PubMed 文献 · Am J Ophthalmol · 2026-05-02

本文回顾性分析了2015至2025年美国开展的2期和3期视网膜干预性临床试验的失败模式。结果显示,糖尿病黄斑水肿、糖尿病视网膜病变、新生血管性年龄相关性黄斑变性和地图样萎缩均存在高脱落率;2期试验多在期中分析后终止,3期试验则更常未达到主要疗效终点。终点选择、对照选择和人群异质性差异以及申办方层面的因素均可能与试验终止相关。

要点

  • 2期试验常在期中分析后终止,3期试验更常未达主要疗效终点。
  • 糖尿病黄斑水肿、糖尿病视网膜病变、新生血管性年龄相关性黄斑变性和地图样萎缩均见高脱落率。
  • 终点选择、对照选择和人群异质性差异可能削弱治疗效果。

核心结论

  • 将早期研究结果转化为成功的后期结局在视网膜药物开发中仍具挑战性。
  • 改善生物学依据、终点选择与操作可行性的匹配可能提高试验成功率。

研究设计与样本

  • 基于2015至2025年美国2期和3期视网膜干预性临床试验失败案例的回顾性分析,采用视角文章形式。
  • 纳入终止、撤回或完成但未达到主要终点的失败试验,按适应症、试验分期、干预类别和作用机制进行评估。

主要发现

  • 糖尿病黄斑水肿、糖尿病视网膜病变、新生血管性年龄相关性黄斑变性和地图样萎缩均观察到高脱落率。
  • 2期试验更常在期中分析后终止,3期试验更常未达到主要疗效终点。
  • 后期研究伴随样本量增加、地理分散、随访时间延长和评估负担加重。
  • 终点选择、对照选择和人群异质性差异可能贡献于治疗效应的衰减。
  • 战略和财务考虑等操作和申办方层面因素也与试验终止相关。

临床怎么用

  • 在视网膜药物开发中应重视生物学依据、终点选择与操作可行性的匹配以提升试验成功率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze patterns of nonsuccess in phase 2 and 3 interventional retinal clinical trials conducted in the United States between 2015 and 2025. DESIGN: Perspective based on retrospective analysis of unsuccessful clinical trials. METHODS: Unsuccessful trials that were terminated, withdrawn, or completed without meeting primary endpoints were evaluated across indications, trial phases, intervention classes, and mechanisms of action to identify recurring design, feasibility, and operational challenges. RESULTS: High attrition rates were observed across diabetic macular edema, diabetic retinopathy, neovascular age-related macular degeneration, and geographic atrophy. Phase 2 trials were more frequently discontinued following interim analyses, whereas phase 3 trials more often failed to meet primary efficacy endpoints. Later-phase studies were associated with increased sample size, geographic dispersion, follow-up duration, and assessment burden. Differences in endpoint selection, comparator choice, and population heterogeneity may contribute to attenuation of treatment effects. Operational and sponsor-level factors, including strategic and financial considerations, were also associated with trial discontinuation. CONCLUSIONS: Translating early-stage findings into successful late-phase outcomes remains challenging in retinal drug development. Improved alignment of biological rationale, endpoint selection, and operational feasibility may enhance trial success.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Tran J, Chhablani J. Unsuccessful Clinical Trials in Retina: Lessons Learned. Am J Ophthalmol. 2026. PMID: 42082070. doi:10.1016/j.ajo.2026.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。